10-K/A: AEON Biopharma Restates 2023 Financials Due to Accounting Error, Cites Going Concern Uncertainty

AEON Biopharma files an amended annual report restating its 2023 financials due to an accounting error related to acquired research and development, and expresses substantial doubt about its ability to continue as a going concern.

Summary

• AEON Biopharma has filed an amended annual report to restate its financial statements for the year ended December 31, 2023, and the quarterly period ended September 30, 2023.
• The restatement was due to an error in how the company recorded the write-off of acquired in-process research and development (IPR&D).
• The error resulted in a $348 million increase in the reported loss for the Successor periods from July 22, 2023 to September 30, 2023 and July 22, 2023 to December 31, 2023.
• The company's management has determined that material weaknesses existed in its internal controls as of December 31, 2023.
• The company has also expressed substantial doubt about its ability to continue as a going concern due to uncertainties around its ability to raise additional capital.
• AEON Biopharma is a clinical-stage biopharmaceutical company focused on developing ABP-450 for debilitating medical conditions.
• The company has completed a Phase 2 study of ABP-450 for cervical dystonia and is conducting a Phase 2 study for migraine.
• Topline data from the episodic migraine cohort of the Phase 2 study was reported in October 2023, and interim topline data from the chronic migraine cohort was reported in May 2024.
• The company has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.

Sentiment

Score: 3

Explanation: The document reveals significant financial and operational challenges, including a restatement, material weaknesses in internal controls, and a going concern warning. While there are some positive aspects, such as the completion of a Phase 2 study for cervical dystonia, the overall tone is negative due to the financial instability and clinical trial setbacks.

Positives

• The company has completed a Phase 2 study of ABP-450 for cervical dystonia with positive results.
• The company has exclusive development and distribution rights for therapeutic indications of ABP-450 in key markets.
• The company has a management team with experience in botulinum toxin development and commercialization.

Negatives

• The company restated its 2023 financials due to an accounting error.
• The restatement increased the reported loss by $348 million for the Successor periods.
• Management identified material weaknesses in internal controls as of December 31, 2023.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The Phase 2 clinical trial for episodic migraine did not meet its primary endpoint.
• The preliminary top-line results from the planned interim analysis of the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine did not meet the primary or secondary endpoints.

Risks

• The company's management has concluded that uncertainties around its ability to raise additional capital raise substantial doubt about its ability to continue as a going concern.
• The company will require additional financing to fund its future operations, and any failure to obtain additional capital could force the company to delay, limit, reduce or terminate its operations.
• The company's future success depends entirely on the successful and timely regulatory approval and commercialization of ABP-450.
• Clinical product development involves a lengthy, expensive and uncertain process.
• Even if ABP-450 receives regulatory approval, it may fail to achieve broad market acceptance.
• The company faces significant competition in the botulinum toxin market.
• The company relies on the Daewoong Agreement for exclusive rights to commercialize and distribute ABP-450, and any termination or loss of rights would materially affect the company.
• The company relies solely on Daewoong to manufacture ABP-450, and any production problems could adversely affect the company.
• Third-party claims of intellectual property infringement may prevent or delay the company's development and commercialization efforts.
• The company's business and products are subject to extensive government regulation.
• The price of the company's common stock may be volatile.
• Sales of a substantial number of the company's securities could cause the price of the common stock to fall.

Future Outlook

The company expects to continue to incur significant expenses and increasing net operating losses for the foreseeable future as it seeks regulatory approval, prepares for and, if approved, proceeds to commercialization of ABP-450.

Management Comments

• Management has concluded that uncertainties around our ability to raise additional capital raise substantial doubt about our ability to continue as a going concern.
• The Company will continue to evaluate the complete dataset and determine the next steps in the development of ABP-450.
• Additionally, the Company has immediately commenced cash preservation measures and will review all strategic options.

Industry Context

The global therapeutic botulinum toxin market is forecast to grow from $3.0 billion in 2020 to an estimated $4.4 billion in 2027, according to the Decision Resources Group Therapeutic Botulinum Toxin Market Analysis Global as of 2021. This market growth is expected to be driven primarily by growth in the number of procedures, which is expected to grow from 2.7 million in 2020 to an estimated 5.0 million in 2027, as well as multiple other factors.

Comparison to Industry Standards

• The company's primary competitors in the injectable botulinum toxin market are Botox, Dysport, Xeomin, Myobloc, and Daxxify.
• Botox is the market leader with approximately 85% of the global therapeutic market share for botulinum toxins and 95% of the United States therapeutic market share for botulinum toxins in 2019.
• Dysport and Xeomin each have approximately 2% of the global market share for therapeutic botulinum toxin treatments.
• The company believes that ABP-450 has a similar 900 kDa molecular weighting to Botox, which will facilitate physician adoption of ABP-450 more rapidly and sustainably than other botulinum toxins that compete with therapeutic uses of Botox.
• The company is seeking to develop ABP-450 for the prevention of migraine and is conducting a Phase 2 clinical study, which is ongoing with respect to chronic migraine, in this indication.
• Botox is the only botulinum toxin approved by the FDA for prophylaxis of headaches in adult patients with chronic migraine.
• There is no botulinum toxin approved for prevention of episodic migraine.

Legal Proceedings

• Odeon Capital Group LLC filed a lawsuit against the company alleging failure to pay a deferred underwriting fee of $1.25 million.

Stakeholder Impact

• Shareholders face the risk of significant losses due to the company's financial instability and potential inability to continue as a going concern.
• Employees may experience job insecurity due to the company's financial challenges.
• Customers and patients may face uncertainty regarding the availability of ABP-450 due to the company's financial and operational challenges.
• Suppliers and creditors may face increased risk of non-payment due to the company's financial instability.

Next Steps

• The company will continue to evaluate the complete dataset from the Phase 2 trial with ABP-450 in the preventative treatment of chronic migraine and determine the next steps in the development of ABP-450.
• The company has immediately commenced cash preservation measures and will review all strategic options.
• The company is actively attempting to secure additional capital to fund its operations.
• The company is in discussions with the FDA regarding the design of its Phase 3 study in cervical dystonia, which it expects to commence based on the availability of capital resources.

Key Dates

Keywords

Botulinum Toxin, ABP-450, Biopharmaceutical, Clinical Trials, Migraine, Cervical Dystonia, Gastroparesis, Regulatory Approval, Financial Restatement, Going Concern